Irene García-García

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years

Alberto M. Borobia, Irene Dapía, Hoi Y. Tong et al. · Clinical and Translational Science · 2017 · 51 citations · Full text

Medicine, Genetics, Pharmacology +16

“The 3/3 Strategy”: A Successful Multifaceted Hospital Wide Hand Hygiene Intervention Based on WHO and Continuous Quality Improvement Methodology

Gabriel Mestre, Cristina Berbel, Purificación Tortajada et al. · PLoS ONE · 2012 · 50 citations · Full text

Health Professions, Health Services Administration, Quality Management +15

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Pilar García‐Alfonso, Miriam Saiz‐Rodríguez, R. Mondéjar et al. · Clinical & Translational Oncology · 2021 · 49 citations · Full text

Medicine, Oncology, Pharmacology +17